ABSTRACT
Accurate and precise diagnosis of hematolymphoid proliferations requires the integration of clinical, pathologic, immunophenotypic, cytogenetic, and molecular genetic findings. 1, 2 While the presence of clonality is not synonymous with malignancy, most malignant lymphoid proliferations are composed of a clonal lymphoid population, which may serve as a marker for malignancy. 3 In lymphoid tissues, clonality has been studied for over four decades to detect monoclonal proliferations to aid in the diagnosis of B-cell lymphomas. 4, 5 In B cells, immunoglobulin light chain restriction can also be assessed as a marker of clonality using immunologic methods, including immunohistochemistry and flow cytometric immunophenotyping; however, in T cells, clonality is assessed primarily by molecular methods. The process of antigen receptor gene rearrangement occurs physiologically in germline lymphoid cells as a mechanism to create normal immunologic diversity. 6 Following the identification of immunoglobulin and T-cell receptor gene rearrangements as clonal markers of B-and T-cell lymphomas, respectively, 7, 8 clonality by molecular methods was initially examined by Southern blot hybridization [8] [9] [10] and subsequently also by polymerase chain reaction (PCR), 11 enabling detection of gene rearrangements in paraffin-embedded tissues. Diagnostic approaches for detecting clonality in non-Hodgkin lymphomas were previously reviewed. 12 Guidelines for detecting clonality by PCR assays were established by a consortium in Europe, [13] [14] [15] now termed the Euroclonality group.
During T-cell development, the T-cell receptor γ (TRG) gene rearranges early in precursor cells and is not deleted, unlike the T-cell receptor δ gene. The TRG gene family is consistently rearranged before the T-cell receptor β (TRB) gene cluster and may also be rearranged in neoplasms of γδ T cells, thus allowing detection of gene rearrangements in most T-cell neoplasms by PCR assays. [16] [17] [18] [19] Furthermore, in contrast with the TRB gene, the TRG locus, located on chromosome 7p14, comprises a restricted germline repertoire of variable (Vγ) and joining (Jγ) gene segments, facilitating detection of clonal rearranged Vγ-Jγ sequences using PCR assays. 3, 13, 16 Theoretically, if all functional variable (V) and joining (J) regions within an antigen receptor gene are evaluable for V-J rearranged cell populations, as is possible with TRG, false-negative results would not be expected for detecting clonal T-cell populations. Therefore, evaluation of TRG gene rearrangements is preferred for T-cell clonality assessment.
The need for a comprehensive set of primers to detect TRG gene arrangements in assessing T-cell clonality by PCR was recommended by Arber et al 20 based on findings from a multi-institutional study of 24 different laboratories from the United States, and the effectiveness of the PCR capillary electrophoresis-based technique to detect TRG clonality using a comprehensive set of primers was demonstrated by Greiner and Rubocki 21 and Lawnicki et al. 22 Currently, most diagnostic laboratories, including at our institution, use PCR assays for the detection of clonality in hematolymphoid tissues. Nonetheless, with the enormous reduction in the cost of next-generation sequencing (NGS) in the past decade, NGS assays are now being increasingly used in clinical pathology laboratories. For this study, our objectives were as follows: (1) to assess the technical feasibility of T-cell clonality assessment by TRG NGS in routine, clinically submitted hematopathologic tissue samples and (2) to compare the NGS findings with those of TRG PCR assays, to determine advantages, if any, for the routine use of NGS assays in comparison with PCR assays for clonality assessment in routinely examined clinical hematolymphoid tissues.
Materials and Methods

Study Design and Case Selection
We analyzed TRG clonality by two commercially available assays, one for TRG NGS and the second for TRG PCR (v2.0), in 41 archived, deidentified samples with hematopathologic diagnoses based on integrated clinicopathologic information, including pathologic evaluation by morphology, histopathology, immunophenotyping by flow cytometry and/or immunohistochemistry, and molecular genetic analysis, as clinically indicated. Of 41 cases, 29 were selected for study from all consecutive clinical samples submitted for T-or B-cell clonality assessment. All samples included and described in this study were collected during a period of 9 months: July 2013 to early January 2014 for peripheral blood (PB) and bone marrow (BM) aspirate samples, as well as July 2013 to late March 2014 for formalin-fixed, paraffin-embedded (FFPE) tissue samples. Inclusion of a case in the study was based on the availability of residual DNA after clinical reporting and if with available clinical information, in an attempt to include major clinicopathologic entities for which T-cell clonality assessment is clinically requested in routine diagnostic hematopathology. For those 29 cases, TRG clonality was previously clinically reported (R.K. and W.W.G.), as assessed by a two-tube, multidistribution TRG PCR assay (cat. 1-207-0051; Invivoscribe, San Diego, CA), but individual case results of our diagnostic TRG PCR assay, including clonal or polyclonal or with low amplification, were not considered a criterion for including a case in the study. During that time period (2013-2014), our T-cell clonality assessment for clinical cases included TRB Southern blot hybridization, using standard procedures, for submitted nonfixed samples that were negative for a T-cell clone by TRG PCR if DNA quantity was sufficient and if a B-cell clone was also not detected in cases where both T-and B-cell clonality tests were requested. Based on all available clinicopathologic information, cases were grouped (R.K.) into three diagnostic categories: (1) benign, with no concurrent or previous lymphoproliferative disorder (LPD), (2) definitive diagnosis of LPD, and (3) atypical LPD with diagnoses concerning but not definitive of LPD.
Paraffin blocks were retrieved for 15 additional FFPE cases, kindly provided by Jonathan Said, including five benign lymph nodes, five mature B-cell neoplasms, and five mature T-and natural killer (NK)-cell neoplasms, including one extranodal NK/T-cell lymphoma, nasal type, and one angioimmunoblastic T-cell lymphoma also associated with a B-cell lymphoproliferative process. Fresh 10-μm sections were cut from those 15 paraffin blocks, which included cases biopsied and fixed outside our institution. DNA was extracted from those sections for the v2.0 TRG PCR and the NGS assays, and the v2.0 TRG PCR assay was done in all 41 included study cases by very experienced technologists from our clinical molecular laboratory, following the manufacturer's instructions and assistance. The v2.0 TRG PCR was analyzed (R.K.) first without knowledge of the clinical case or the diagnostic two-tube PCR assay results using the same peak height (at least twice the height of the highest peak in the polyclonal background) for clonal peaks, as for our diagnostic
Excluded Cases
Five LPD FFPE cases, including two additional cases from our clinical molecular laboratory and three from the retrieved paraffin blocks, were excluded from the study at a later stage described below, after our assessment for quality of DNA or at library preparation. In two of these five cases, DNA was completely degraded and we did not even attempt library preparation. In the remaining three of five cases, despite observing degradation of DNA, we attempted to get a DNA library but were unsuccessful. The excluded cases included two with paraffin blocks from the year 2007 (>6 years prior to study), one with B5-fixed tissue (cut accidentally instead of FFPE block), one skin punch biopsy specimen from 2013, and one lymph node case involved by a B-cell lymphoma, from 2013, with low DNA amplification in our B-cell clonality assay.
Clinicopathologic Diagnoses and Sample Sources
The clinicopathologic diagnoses for the 41 cases finally included in our study in the three groups, as described above, are given in ❚Table 1❚, as per the revised fourth edition of the World Health Organization classification. [23] [24] [25] [26] Patient demographics (age and sex) and sample sources are given in ❚Table 2❚. For the included FFPE cases, paraffin blocks in 16 of 18 cases were from 2013 (age of paraffin block <1 year at library preparation for NGS), and one each was from 2012 and 2010.
Clinical Molecular Diagnostic Methods for T-Cell Clonality Analysis
We used standard methods for DNA extraction and amplification, as in a clinical laboratory, with detection of fluorescent-labeled rearranged PCR products by capillary electrophoresis using POP-7 polymer (cat. 4352759; Applied Biosystems, Foster City, CA) as the separation matrix on an ABI 3130xl sequencer (Applied Biosystems). For all diagnostic PB samples in this study, DNA was extracted in our clinical laboratory using either an automated instrument (Beckman Sprite nucleic acid extractor; Beckman Coulter, Brea, CA) or a manual kit (Puregene Blood Core kit C, cat. 158389; Qiagen, Valencia, CA), depending on the workflow of the laboratory at the time of test request, with the latter kit (Puregene) solely used for BM aspirate samples. For FFPE cases, DNA was extracted using the QIAamp DNA Mini Kit (cat. 51304; Qiagen) from 5-μm sections for the archived DNA cases and the QIAamp DSP DNA FFPE tissue kit (cat. 60404; Qiagen) for the additional paraffin block sections. DNA was quantified using a spectrophotometer (NanoDrop 2000; Thermo Scientific, Canoga Park, CA). Separate, parallel DNA amplification reactions were set up in duplicate with 100 ng DNA input. PCR cycling conditions were 95°C (3 minutes), followed by 35 cycles of 94°C (30 seconds), 55°C (30 seconds), and 72°C (1 minute), with the final phase at 72°C (10 minutes). Appropriate polyclonal and 5% sensitivity positive controls and a no-template DNA reaction were included and analyzed in each assay run as per standard laboratory procedures. Our interpretive guidelines for the TRG PCR assay for our molecular diagnostic laboratory were as follows: to report the presence of a clonal T-cell population, we required a discrete, reproducible PCR product peak to be present in at least one of the four primer sets analyzed in the assay, with the peak height at least twice the height of the highest peak in the background polyclonal amplified product peaks. We considered three or more such clonal peaks as not indicative of monoclonality but instead as evidence of an oligoclonal T-lymphoid cell population if these multiple PCR product peaks were exactly reproducible in duplicate runs. We used caution in interpreting peaks in samples with low or erratic amplification signals since peaks in such samples are not truly indicative of clonality and instead usually represent low numbers of targeted cells. We examined the expected nucleotide size regions in the assay for the clonal peaks, but we carefully considered peaks outside these regions, if any, with additional efforts to resolve all findings as necessary for the diagnostic interpretation.
TRG NGS Assay and the v2.0 Single-Distribution TRG
PCR Assay
We analyzed all included study cases using the LymphoTrack TRG NGS assay for the MiSeq (cat. 7-227-0009; Invivoscribe) and a single-tube, single-distribution TRG Gene Rearrangement v2.0 PCR assay (cat. 1-207-0101; Invivoscribe). The v2.0 TRG PCR assay contains V and J region primers that target all functional rearranged TRG gene segments, with amplification products in a small size range (159-207, average 190 nucleotides). The NGS assay contains primer master mixes that target regions similar to those targeted in the TRG v2.0 PCR assay. Also, the single-tube TRG PCR assay was previously compared with the multidistribution BIOMED-2-based TRG PCR assay and was easier to interpret than the BIOMED-2 assay in that study, with sensitivity similar in both assays. 27 Therefore, we designed our study to also analyze the TRG v2.0 PCR assay in all of our study cases, to enable the best possible comparison of NGS with fragment-length PCR, including for comparison sequence lengths of clones by NGS with nucleotide sizes of clonal peaks by the single-distribution v2.0 PCR assay.
In all cases, before proceeding to the NGS procedure and with the v2.0 PCR assay, DNA concentration and purity (NanoDrop, Thermo Scientific), as well as DNA integrity (1% agarose gel), were assessed to ensure high-quality genomic DNA in all samples. The above-described five FFPE samples were excluded from the study at this step. The NGS assays and the comparative single-distribution v2.0 PCR assays were set up as single amplification reactions (L.D.). For the v2.0 PCR assay, the same DNA input (100 ng), cycling conditions, and instruments, including the same ABI sequencer, were used, with appropriate controls as per standard laboratory procedures, as for the diagnostic PCR assay.
For NGS, the DNA samples were diluted into a final concentration of 100 ng/µL in water, and 500 ng DNA input was used for all samples. For the LymphoTrack assay, PCR reactions used 5 µL of template (samples, positive, negative or water), 45 µL of appropriate master mix, and 0.25 µL of AmpliTaq Gold DNA polymerase (Life Technologies, Austin, TX). Twenty-seven PCR cycles were performed (95°C for 7 minutes, 95°C for 45 seconds, 60°C for 45 seconds, and 72°C for 90 seconds), followed by 72°C for 10 minutes, and held at 4°C. Purification by binding of amplicons to magnetic beads (Agencourt AMPure XP; Beckman Coulter) in a bead/amplicon ratio of 1:1 was followed by incubation at room temperature for 10 minutes, left on the magnetic plate for 5 minutes, and dual washed with 200 µL 80% ethanol. After air-drying for 5 minutes, the purified amplicons were eluted in 25 µL buffer (10 nmol/L Tris-HCl, pH 8.0), and 22.5 µL of each sample was transferred to a fresh tube. The yield of the purified products was checked by using the DNA High Sensitivity chip on the Agilent Bioanalyzer (Agilent, Waldbronn, Germany). The concentration of the amplicons was checked by Qubit 2.0 (Life Technologies, Eugene, OR) following the manufacturer's instructions, and the amplicons were quantitated using the nmol/L = (ng/µL concentration) × 10 6 /660 × β, with β = 300 base pairs. The libraries were pooled to a final concentration of 1 nmol/L and the final library prepared for MiSeq sequencing using the MiSeq v2 Reagent kit (Illumina, San Diego, CA), followed by loading 600 µL of the final prepared library onto a MiSeq reagent cartridge. After overnight sequencing on the MiSeq, the fastq files were saved in Basespace (Illumina), checked for quality, and then imported to and further analyzed (R.K.) using the bioinformatics software (original version with nonmerged reads) provided by the manufacturer with the LymphoTrack TRG assay.
Interpretation of TRG Clonality by NGS in All Cases
Since no established criteria yet exist for interpreting clonality by NGS, we used a combination of steps and multiple criteria to assess clonality by NGS, including the following: (1) knowing the clinicopathologic situation in which the clonality analysis was clinically requested (eg, rule out a T-cell clone in a patient with cytopenia and no definite cause yet established for the cytopenia) or knowing the definitive pathologic diagnosis where we would expect a clone such as in a T-cell lymphoma or a T-cell LPD (T-LPD). Since it is well known that any individual can have a T-cell clone present at any time in PB for multiple reasons, even in the absence of a T-cell neoplasm or a T-cell LPD, and since even non-NGS molecular techniques, including PCR, are well known to detect physiologic or nonneoplastic lymphoid clones, it must be noted that for our study, we refer to a "clone" regardless of whether any detected clone could be physiologic or pathologic, with the latter including clones in nonneoplastic and neoplastic (lymphoproliferative) diseases. (2) We reviewed the PCR results of the case as clonal, with biallelic or monoallelic clones, as are currently considered as such by fragment-length PCR, or as polyclonal with sharp peaks that could represent clones within the polyclonal population or insufficient target cells (by the PCR capillary electrophoretic pattern) that we also confirmed by the clinicopathologic situation. We compared the PCR assay findings, including nucleotide sizes of discrete PCR product peaks in the v2.0 assay by capillary electrophoresis, wherever possible with the NGS data, including the sequence lengths, to determine whether the NGS results were concordant with the PCR findings and if NGS results could be relied on in every case. Therefore, having the PCR findings was necessary before reliably 
Results
T-Cell Clonality
Results by the Two-Tube TRG PCR and v2.0 TRG PCR Assays ❚Table 3❚ shows T-cell clonality results of the twotube, multidistribution, TRG PCR assay at the time of diagnosis in 29 of 41 cases, distributed according to the sample types (PB, BM, and FFPE tissues) and the three diagnostic study groups (diagnostic LPD, no LPD, and atypical LPD).
❚Table 4❚ shows T-cell clonality results by the two-tube PCR and v2.0 PCR assays in each of 10 PB and six BM cases with no concurrent or previous LPD. The quantity of DNA was sufficient for TRB Southern blot in one case (designated PB2). In two additional cases designated PB3 and BM2, the quantity of DNA was insufficient for Southern blot analysis. In 10 PB cases, by the two-tube PCR, six were clonal, one was borderline clonal, and three were negative for a clonal population. In comparison, by the v2.0 PCR, only two were clonal (both also clonal by the two-tube assay), and the remaining eight cases were negative for a clone (including two negative cases and one borderline case by the two-tube PCR). Concordant PCR results for clonality were present in five (50%) of 10 cases (three negative and two positive for a clone). In the remaining five (50%) PB cases (cases designated NLPD1, NLPD3, NLPD4, NLPD6, and NLPD7), including four with cytopenia and one with leukoerythroblastosis, a clone, including a borderline clone, was present by the two-tube PCR but not by the v2.0 PCR.
In six BM cases, concordance between both PCR assays was present in five (83%) of six cases, including two negative for a clone and three clonal cases, which included two with oligoclonal populations. The single discordant case (NLPD9) with pancytopenia showed a clone by the two-tube PCR but not by the v2.0 PCR. In total, for all PB and BM cases with no concurrent or previous LPD, discordance was observed in six (37%) of 16 cases (five PB, one BM), all of which were clonal by the two-tube PCR and negative by the v2.0 PCR.
❚Table 5❚ shows the results of both PCR assays in five PB and two BM LPD cases. The results were concordant in three of five PB cases (LPD1, LPD4, and LPD5). In one discordant PB case (LPD3) with a diagnosis of mycosis fungoides, a clone was present by the two-tube PCR but not by the v2.0 PCR, and in the fifth case (LPD2), the two-tube PCR showed an equivocal clone, while the v2.0 PCR was negative. Both PCR assays were clonal in both BM LPD cases.
Collectively, for all 15 PB and eight BM cases, the two-tube PCR and v2.0 PCR assay results were discordant in eight (35%) of 23 cases, including seven (46%) of 15 PB cases and one (12.5%) of eight BM cases, wherein the two-tube PCR was clonal while the v2.0 PCR was not diagnostic of a clone.
❚Table 6❚ shows the results of both PCR assays for all FFPE cases, including nine diagnostic LPDs, four atypical LPDs, and five FFPE benign lymph nodes. The v2.0 PCR was positive for the presence of a clonal population in all four mature T-cell neoplasms and one diffuse large B-cell lymphoma, non-germinal center B-cell type, and it showed a borderline clonal peak in one posttransplant LPD, plasmacytic type. In contrast, the two-tube PCR was negative for a T-cell clone in the posttransplant LPD case (LPD16) and equivocal in one mature T-cell lymphoma (LPD8). The v2.0 PCR did not show a diagnostic clone in any of the four atypical LPDs, while the two-tube PCR showed no clone in two of four atypical LPDs but was clonal in two atypical LPDs (ALPD1 and ALPD2). The same sample was negative for a B-cell clone by PCR; DNA quantity not sufficient for SB. The same sample was positive for a B-cell clone by PCR.
T-Cell Clonality Results by TRG NGS
Technically, we found high DNA quality to be the most critical factor for successful NGS analysis, with sizes of FFPE tissues we studied comprising small endoscopic and excisional biopsy and resection specimens, including three prefixation frozen tissues. In our NGS sequencing runs, 23 
Clonal T-Cell Populations by NGS
These comprised unique, single or multiple, dominant rearranged Vγ-Jγ sequences of different or similar nucleotide sizes within single or multiple Vγ-Jγ regions within a case, as shown in composites ❚Figure 1❚, ❚Figure 2❚, ❚Figure 3❚, ❚Figure 4❚, and ❚Figure 5❚. The true nature of clonal populations detected by v2.0 PCR, including biallelic or monoallelic or possibly multiple clones, sequence variation within neoplastic clonal populations, and the relative proportions of T-cell clones (benign or neoplastic) among polyclonal or total T cells, was characterized by NGS. The sequence lengths of clones by NGS were concordant with nucleotide sizes by v2.0 PCR. Notably, in our study, a definitive diagnosis for the presence or the absence of a clonal population, also with an estimate of the minimum relative proportions of the clonal populations, when present, within the total T cells, was possible in all 41 studied cases by NGS. In contrast, by post-PCR capillary electrophoretic detection, clones were detected only by nucleotide sizes of the clonal PCR product peaks within the expected size range in the TRG v2.0 PCR assay, and the true nature of the clonal peaks as biallelic or monoallelic was discerned only by NGS. Importantly, the relative proportion of the clonal population within all T cells could only be estimated by NGS and not by clonal results in PCR assays.
Our NGS interpretation for TRG clonality is provided for each case, grouped according to specimen sources, as follows: ❚Table 7❚ for PB cases with no LPD, ❚Table 8❚ for BM cases with no LPD, ❚Table 9❚ for PB and BM cases with LPD, ❚Table 10❚ for FFPE benign lymph nodes, and ❚Table 11❚ for FFPE LPD, and ❚Table 12❚ for atypical LPD cases. Each table includes total reads and unique sequences, as well as the most frequent Vγ-Jγ sequences in each case, with the likely composition of the sequences comprising the clonal population, if present, and the minimum percentages of the clonal sequences among all T cells for each case. Supplementary Tables 2 to 4 provide detailed results for NGS and both PCR assays for all 41 cases. Table 7 gives our NGS results in each of the 10 PB cases with no LPDs. In all cases, NGS confirmed the presence of a polyclonal T-cell population characterized by numerous Vγ-Jγ rearranged DNA sequences within diverse Vγ-Jγ regions, with or without an overt dominant clone. Figure 1 illustrates graphical distributions of the top 200 Vγ-Jγ sequences and the entire Vγ-Jγ usage percentages in six PB cases, each with no previous or concurrent LPD. Representative cases are shown for a polyclonal population in Figure 1A (PB1) ; low numbers of target cells, restricted Vγ-Jγ usage, and with no clone in Figure 1B (PB2); a small (~2.4%) monoallelic clone in a polyclonal population in Figure 1C (PB3); a small (~6%) biallelic clone in a polyclonal population in Figure 1D (NLPD2); a small clone (at least 5.5%) in a polyclonal population in Figure 1E (NLPD3); and two biallelic clones comprising ~20% and ~6% of all T cells in Figure 1F (NLPD5). The smallest T-cell clone detected in our study was in case PB3, sequenced with greater than 600,000 reads. The clinical significance or reproducibility of this small clone could not be established in this single time point analysis. Table 8 gives our NGS results in each of the six BM cases with no LPDs, and representative cases are illustrated in composite Figure 2 . Two polyclonal cases with no clone are shown, with the first one positive for a B-cell clone in the same sample in case BM1 (Figure 2A ) and the second negative for a B-cell clone in the same sample in case BM2 ( Figure 2B ). The latter (closest to normal) case shows Vγ10-Jγ1/2 as the most frequent sequence, while a different sequence (Vγ4-Jγ1/2) was the most frequent in the case with a B-cell clone. The same Vγ4-Jγ1/2 region was the most frequent in case NLPD10 ( Figure 2C ), which had only ~25,000 reads, confirming the low numbers of target cells, but in that case, at least a small biallelic clone comprising at least 18% or likely multiple true oligoclones were present. In contrast, case NLPD11 had ample target cells with oligoclones by PCR but showed a small unequivocal biallelic clone (Vγ2-Jγ1/2 and Vγ8-Jγ1/2) by NGS ( Figure 2D ), and case NLPD8 ( Figure 2E ) showed a biallelic clone comprising the same Vγ2-Jγ1/2 and Vγ8-Jγ1/2 regions as in case NLPD11. Table 9 gives our NGS results in each of seven PB and BM cases with LPDs, and all cases are illustrated in composite Figure 3 . In all cases, NGS confirmed or revealed the presence of a monoallelic or biallelic clones and characterized the minimum percentage of the clone within all T cells. Overt, dominant Vγ-Jγ clonal sequences were present in PB in a case of cutaneous CD30+ T-LPD (LPD4; Figure 3D ) and in the BM (LPD6; Figure 3E ) in a case with T-cell large granular lymphocytic leukemia (T-LGLL). Small clones were present within a polyclonal T-cell population that were not identifiable or were nondiagnostic by v2.0 PCR in PB in a case of Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (LPD2; Figure 3B ) and in a PB case of active mycosis fungoides (LPD3; Figure 3C ). At least two biallelic clones were present in PB (LPD1; Figure 3A ) in a case of Sézary syndrome with large cell transformation of mycosis fungoides, wherein characteristic neoplastic T cells were present by morphology and flow cytometric immunophenotypic analysis of the same PB sample analyzed by NGS. A smaller clone was present in the recurrent T-LGLL case (LPD7; Figure 3F ). The clonal T-cell population in five of these seven cases was present in the same Vγ-Jγ region that had the greatest Vγ-Jγ usage, except in both cases of mycosis fungoides. Table 10 gives our NGS results for all five benign lymph nodes, all of which showed polyclonal T cells with no clone detected by NGS. All three cervical lymph nodes excised during surgical resection procedures showed Vγ10-Jγ1/2 as the most frequent sequence, with one representative cervical lymph node case (LN1) illustrated in Figure 4A . In contrast, a femoral lymph node excised during a surgical resection procedure showed Vγ10-JγP1 as the most frequent sequence. An excised axillary lymph node with follicular and interfollicular hyperplasia showed Vγ11-Jγ1/2 as the most frequent sequence, with several small Vγ10-JγP1 sequences ( Figure 4B ). Table 11 gives our NGS results for all diagnostic FFPE LPD cases, including neoplasms of mature T-cell or mature B-cell origin, and Table 12 gives our results for the atypical FFPE LPD cases. For all four T-cell lymphoma cases (designated LPD8-11), v2.0 PCR showed biallelic clonal populations. NGS showed overt clones comprising at least 44% of all T cells, with a range of 44% to 69% for the neoplastic clones for all four cases. Furthermore, by NGS, only two of those four T-cell lymphoma cases showed a biallelic clonal population, with a representative case of an ALK-negative anaplastic large T-cell lymphoma (ALCL) illustrated in Figure 4C . In the remaining two T-cell lymphoma cases, including another ALK-negative ALCL case, NGS revealed a monoallelic clone, as illustrated in a case of peripheral T-cell lymphoma not otherwise specified ( Figure 4D ). The neoplastic clones in all four of the T-cell lymphoma cases comprised sequences from different Vγ-Jγ regions, but in each case, the most frequent clonal sequence was present in the region with the greatest usage.
TRG NGS Results in PB Cases With No Concurrent or Past LPD
TRG NGS Results in BM Cases From Patients With No Concurrent or Past LPD
TRG NGS Results in PB and BM Cases From Patients With LPDs
TRG NGS Results in FFPE Benign Lymph Nodes
TRG NGS Results in FFPE Diagnostic and Atypical LPD Cases
In contrast, if a T-cell clone was detected in a mature B-cell neoplasm, it was small, as illustrated in Figure 4E in a case of diffuse large B-cell lymphoma (DLBCL), non-germinal center B-cell phenotype, with clonal T cells comprising ~8% of all T cells. As given in Table 11 , the other two cases of DLBCL, including one with germinal center and the other with non-germinal center B-cell phenotype, showed low numbers of target T cells, and a clone was not identified by NGS. Restricted Vγ-Jγ usage with low numbers of T cells was noted in one case (LPD15).
Furthermore, in contrast with mature T-cell lymphomas in our study, in one case (ALPD2) that was classified as atypical with features suspicious for a primary cutaneous CD4+ small/medium T-cell LPD, a small-to intermediate-sized biallelic clonal T-cell population was detected comprising at least 12% and possibly ~17% of all T cells, as illustrated in Figure 4F . Figure 5 illustrates four immune dysregulation-associated LPD cases for which FFPE sections were examined in our study. In one case of an EBV-positive DLBCL not otherwise specified ( Figure 5A ), few target cells were noted, but no clone was identified. In an EBV-positive atypical LPD case ( Figure  5B ), biallelic expansion of the two most frequent sequences was noted, but this expansion was less than four times the third most frequent sequence, which, if it had been present, would have led us to suspect a small borderline clone present among polyclonal T cells. The other EBV-positive atypical LPD case did not show any evidence of a clone ( Figure 5C ), while a small biallelic clone was present in a case of a posttransplant LPD ( Figure 5D ). Interestingly, in ❚Figure 1❚ (cont) E, PB with small clone in polyclonal population, comprising at least 5.5% of all T cells; case NLPD3, leukoerythroblastosis due to metastatic breast carcinoma in bone marrow. F, PB with a clonal population comprising two biallelic clones, ~20% and ~6%; case NLPD5, bicytopenia. all four FFPE cases with immune dysregulation either due to EBV positivity or posttransplantation, the overall usage of Vγ10-JγP1 was increased (relative or absolute), while the most frequent sequence was present in the same Vγ10-JγP1 region only in the EBV-positive DLBCL not otherwise specified case ( Figure 5A ), as illustrated in Figure 5 .
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Comparison of TRG NGS Results With v2.0 TRG PCR ❚Table 13❚ shows a comparison of the results for NGS and v2.0 PCR assays in all PB and BM benign cases with no LPD. In four (25%) of those 16 cases, NGS revealed small clones ranging from ~2.4% to ~7% within polyclonal populations, which could not be diagnosed by v2.0 PCR in three (75%) of four cases. One case with a small ~6% clone was detected as clonal by v2.0 PCR. In both BM cases where oligoclones were detected by PCR, including in one case with few target cells (NLPD10), NGS clarified the nature of the clones as comprising at least 18% and at least 12% of all T cells, respectively. Similarly, in two additional cases that were clonal by v2.0 PCR (PB case NLPD5 and BM case NLPD8), NGS characterized the nature of the clones and percentages within all T cells. In the remaining eight (50%) cases in this group, v2.0 PCR showed either no clone or sharp peaks not diagnostic of clones, and NGS confirmed the absence of a clone in all of those eight cases.
❚Table 14❚ shows a comparison of the results for NGS and v2.0 PCR assays in all PB and BM LPD cases. In the case of an EBV-positive mucocutaneous ulcer and the case of concurrent and long history of mycosis fungoides, v2.0 PCR was not diagnostic for clones, but NGS revealed small clones in each case, as also illustrated. In the PB case with pancytopenia and oligoclones by PCR, NGS revealed the presence of a biallelic large clonal population comprising at least 28% of all T cells. In the case of mycosis fungoides with Sézary syndrome, NGS confirmed the presence of a clonal population comprising at least 12% of all T cells, clarifying the nature of clonal peaks by PCR. Similarly, in both BM cases with T-LGLL, NGS clarified the minimum percentages of clones identified as clonal by v2.0 PCR. In all three PB and BM cases wherein v2.0 PCR suggested few target cells, NGS confirmed low numbers of target cells.
Collectively, in all 15 PB study cases, NGS revealed small clones in five (33%) cases, including three benign cases with no LPD and two LPD cases that were not diagnostic for the presence of a clonal population by v2.0 PCR.
❚Table 15❚ shows a comparison of the results for NGS and v2.0 PCR assays in all FFPE cases, including diagnostic and atypical LPD cases, and the five benign lymph nodes. Results were concordant for the presence of a clonal population in all four mature T-cell lymphomas, except for a monoallelic clone by NGS in two cases, as described above in NGS results, while the v2.0 PCR showed a biallelic clone in all four cases. Notably, in one case of DLBCL, non-germinal center B-cell phenotype, NGS clarified the to findings by v2.0 PCR, which also suggested few target cells. In both FFPE cases wherein v2.0 PCR suggested few target cells, NGS confirmed low numbers of target cells. Overall, for all study cases, NGS revealed the presence of T-cell clonal populations in six (14%) of 41 that were negative for T-cell clones by v2.0 PCR, including three in PB with no prior LPD (PB3, NLPD3, and NLPD6), two in PB with LPD (LPD2 and LPD3), and one FFPE case (ALPD2) of a primary cutaneous CD4+ small/medium T-cell lymphoma. Also, NGS showed relative or borderline expansion of the most frequent sequences in two EBV-positive cases (LPD13 and ALPD1).
Comparison of TRG NGS Results With the Two-Tube
Multidistribution TRG PCR ❚Table 16❚ shows a comparison of the results for NGS and the two-tube PCR assays in all PB and BM cases with no LPD. Results were concordant for no clones in four cases and for the presence of clones in seven, including two oligoclonal cases. Among the five (31%) of 16 discordant cases, NGS revealed a small clone comprising ~2.4% in one (20%) of five cases that were negative for a clone by two-tube PCR, while NGS was negative for a clone in four cases that were clonal by the two-tube PCR.
❚Table 17❚ shows a similar comparison for all nine LPD and four atypical LPD cases that had prior diagnostic two-tube PCR results. A diagnostic clonal population was present by the two-tube PCR in six of seven PB and BM LPD cases, including the case of mycosis fungoides (LPD3) with a small ~3% clone. The only discordant case was the one with a diagnosis of an EBV-positive mucocutaneous ulcer (LPD2), where the two-tube PCR result was equivocal and a small clone was present by NGS.
In FFPE cases, the two-tube PCR was negative in the posttransplant LPD case that showed a small ~3.5% clone by NGS and was equivocal in the ALK-negative ALCL case. Among four atypical LPD cases, a clone was detected in two cases by the two-tube PCR, one of which (ALPD2) showed a definite clone by NGS. The PCR and NGS findings were concordant in the remaining two atypical LPD cases.
Furthermore, the two-tube PCR was positive in five (NLPD3, NLPD6, LPD2, LPD3, and ALPD2) of the six cases in this study that were clonal by NGS but were negative for a clone by v2.0 PCR. On the other hand, four additional cases were clonal by the two-tube PCR but were negative for a clone by NGS (NLPD1, NLPD4, NLPD7, and NLPD9).
Overall Comparison of NGS With Both PCR Assays in All Cases
An overall summary of both PCR and NGS results for the presence of a clonal T-cell population is provided in Supplementary Table 5 . Overall, NGS revealed the presence of T-cell clonal populations in eight (19%) of 41 cases that were negative for T-cell clones by PCR. These cases included three benign PB cases (negative by v2.0 PCR), two LPD PB cases (negative by v2.0 PCR), two LPD FFPE cases (negative by two-tube PCR), and one atypical LPD skin FFPE case (ALPD2, negative by v2.0 PCR). In two of these PB cases (one benign, one LPD) that were positive for clones by NGS, both TRG PCR assays were nondiagnostic for clones. Furthermore, in an additional five (12%) of 41 nonneoplastic cases (three benign PB cases, one benign BM case, and one atypical LPD FFPE case) with the two-tube PCR positive for T-cell clones, NGS confirmed the presence of polyclonal T-cell populations in the absence of any clones.
Discussion
❚Table 18❚ shows a comparison of our study with three publications wherein NGS and PCR assays were used for evaluation of T-cell clonality, including the goal of the study, criteria for selection of the case cohort, pathologic diseases studied, patient age and sex, sources of tissues E ❚Figure 2❚ (cont) E, BM with biallelic clonal population comprising at least 17% of all T cells, clonal by v2.0 PCR; case NLPD8, posttherapy for carcinoma, peripheral blood with inverted CD4/ CD8 ratio. examined, and sample variables for NGS, including DNA input and DNA integrity, as well as results for the NGS assays used in those studies. [28] [29] [30] Schumacher et al 28 considered PCR-positive clonal samples as the standard for clonality, and as per their publication (p. 357, left column, top paragraph), "for initial assessment of clonality, the sensitivity of their NGS assay was not substantially different from capillary electrophoresis based assays." Furthermore, in that report, 28 the cases described as indeterminate by NGS could be explained by NGS criteria that we have used in our study. Sufficool et al 29 44% (15/35) by PCR in FFPE cases of mycosis fungoides, using an average of close to a million sequencing reads per case, also by using a percentage of top sequences among all reads as the criterion for clonality. It is unclear from the report whether DNA integrity was examined for the archived DNA samples, all of which were extracted from FFPE skin biopsy specimens. 29 Kirsch et al 30 examined frozen skin punch biopsy specimens and found NGS to be more sensitive than TRG PCR in cases of cutaneous T-cell lymphomas, including mycosis fungoides. Kirsch et al 30 also examined PB samples from patients with mycosis fungoides by NGS and found small percentages of circulating neoplastic cells, similar to the two PB LPD cases in our study from patients with mycosis fungoides, including one with Sézary syndrome. We did not examine cutaneous FFPE tissues with mycosis fungoides because in our (X.L.) experience, DNA is often degraded in FFPE skin biopsy specimens, as was also stated by Kirsch et al, 30 who examined fresh skin punch biopsy specimens, and as we also observed in one skin punch biopsy FFPE case that we excluded.
Our study is novel in describing NGS findings within a spectrum of clinical cases comprising benign, neoplastic, and atypical LPD cases, including mature T-cell lymphomas and newly defined LPD entities in the World Health Organization classification, 2,26 mature B-cell neoplasms, and immune dysregulation-associated LPD cases, including EBV-positive and posttransplant LPD cases. We applied NGS to a clinical case cohort with comprehensive clinicopathologic information, keeping in mind the clinical indication for the request for clonality evaluation. Additional innovative aspects of our study include the use of NGS in the primary analysis of clonality irrespective of PCR assay findings and the detection of small clones in samples other than skin or PB from patients with diagnoses other than cutaneous T-cell lymphomas, including mycosis fungoides that were described by Kirsch et al. 30 Moreover, we provide our NGS data for every case, thereby providing a reference for future studies, and describe our approach for analyzing NGS data, including guidelines for evaluation of TRG clonality, which can be used by any clinical laboratory.
Specifically, in addition to confirming that NGS is more sensitive than v2.0 PCR, our study revealed the presence of small T-cell clones in an overall 14% (six of 41) of cases that were not detectable by v2.0 PCR within a polyclonal T-cell population. These cases included 30% (three of 10) of PB cases with no prior LPD, 40% (two of five) of PB cases with an LPD, and one FFPE case of a primary cutaneous CD4+ small/medium T-cell LPD. The clones detected only by NGS comprised ~2.4%, ~5.5%, and ~7% of all T cells, as also illustrated in the three PB cases with no LPD, and in all three of those cases, the clinical indication for testing was to rule out a T-cell clone. The two PB with LPD cases with clones detected only by NGS included one of two cases with mycosis fungoides in our study and the single case with a diagnosis of an EBV-positive mucocutaneous ulcer. Notably, the twotube, multidistribution TRG PCR assay used for diagnostic reporting detected the presence of clones in five of the above six cases that were negative by the v2.0 PCR, and neither PCR assay could detect the smallest clone ~2.4% in PB by NGS. Our study findings for the discordant results between the two PCR assays are explained by the fact that a multidistribution PCR assay design is more likely to detect clones than single-distribution PCR, as has been previously shown by Cushman-Vokoun et al 27 using a different multidistribution TRG PCR assay. However, our comparison of two PCR assays was only a secondary aspect of our study, with our primary focus on evaluation of initial clonality by NGS, as is evident from the NGS results for every case, as we have reported, including with illustrations, for all three specimen types (PB, BM, and FFPE tissues) with benign, diagnostic, and atypical LPD cases in this study.
We examined all data in an unbiased manner by NGS to detect any clones that could be present in any patient at any time, regardless and without knowledge of the diagnosis, and then applied our NGS findings to the clinical data to understand the variables or criteria that need to be considered when evaluating clonality by NGS in clinical cases, including the following: (1) Total numbers of reads: we considered any number less than 50,000 as relatively low numbers of target cells. (2) Total VJ usage: if around five or more VJ regions out of a total of 32 were not used, we considered that case to have restricted VJ usage. (3) The graphical pattern of the top 200 sequences and the percentages of the top most frequent sequences were important, but always in context of the total numbers of reads, which acted as a surrogate in our study for the absolute number of target T cells. For example, case NLPD10 had only about 25,000 reads but a clear biallelic pattern, as shown in Figure 2C , with a clonal population comprising 18% of all T cells (or about 4,500 actual reads). We consider that clone to be small, despite a much higher sounding number of 18%, because the number of reads was very low, indicating few T cells, which we confirmed by the clinical situation. Conversely, case NLPD1 was an example with low numbers of reads and increased percentages of the top sequences, but we did not consider them to be true clones because there was no increase in absolute numbers of reads in the most frequent sequences. (4) If we found a biallleic clonal population, we added the minimum percentages of the sequences comprising the biallelic clone and examined the remaining sequences to determine how many times greater that biallelic clone was. The sequence that needed to be compared to the clonal sequence could be present in the "polyclonal background" and was not the same in each case and depended on the pattern present in each case (ie, it was not always the second, third, fourth, or fifth most frequent sequence). It is in this aspect, especially for detecting small clones, that our study did not reveal a single criterion. (5) If the clone was monoallelic (ie, if the pattern clearly showed one dominant sequence), then we examined the percentages of the second and third most frequent sequences and tried to determine if the second could be or was not a part of the clone (ie, a biallelic clone) and, if yes, then the third and the next most frequent sequences. (6) Clone size: applying the same steps as described above, in cases with adequate or ample target T cells, we considered clones comprising less than 10% to 12% of all T cells to be small. Overt clones that could be detected with ease could comprise from ~18% (or less) to a much higher proportion, among all T cells, and it is important to note that the software adjusts the y-axis with percentages automatically such that each case shows different numbers on the y-axis. (7) For reasons explained above, we believe that if NGS is to be used for initial assessment of clonality, then applying any single criterion to every case (such as a multiple of the peak height criterion used in PCR assays) will not give a true and sensitive evaluation of clonality that is possible by NGS analysis, given the variables that are virtually always present in examination of routine clinical specimens by molecular analysis and were represented in our study cases. (8) Precise interpretation of NGS clonality assay results critically requires integration with clinical and pathologic findings since preanalytic phase concerns present in PCR clonality assays are also similarly present in NGS-based assays and since the presence of a lymphoid clone by PCR or NGS is not synonymous with a neoplastic or malignant LPD. Notably, using our criteria, our NGS study allowed every case in our study to have a definitive evaluation of clonality, including either to rule out or to rule in a clone, with a quantitative estimate of the clonal population possible only by NGS. In our study, we used commercially available assays that can be validated in house in any clinical molecular laboratory, as opposed to sending out to a reference laboratory, to be able to evaluate NGS findings in light of the clinicopathologic information. Factors to consider when bringing in this assay include, most important, cost and turnaround time, as well as DNA integrity from FFPE tissues if archived tissues are examined. Currently, the cost of the commercially available PCR assays is quite comparable to the cost of the NGS assay, especially if the PCR assay is done in duplicate in a clinical laboratory. The cost ❚Figure 4❚ (cont) E, Small biallelic clonal population, comprising at least 8% of all T cells; case LPD12, diffuse large B-cell lymphoma, non-germinal center B-cell phenotype; FFPE tissue. F, Small biallelic clonal population, comprising at least 12% of all T cells; case ALPD2, primary cutaneous CD4+ small/medium T-cell LPD; FFPE tissue.
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of sequencing and sample volume need to be considered before bringing in the assay. If samples can be batched such that several can be sequenced in one run, then the cost can even be comparable with that of commercial PCR assays. For turnaround time, the NGS sequencing procedure can be completed in 1 week starting from DNA extraction, and the actual time would depend on how long a sample had to wait before getting on to a sequencing run. DNA integrity issues must be considered if solely using NGS for clinical evaluation of TRG clonality since all archived FFPE samples may not qualify for NGS due to degradation of DNA, as we observed in our study in the excluded cases. Using commercial assays, we found that the key difference between interpreting PCR and NGS-based clonality assays is that the polyclonal population identified by PCR has a Gaussian distribution comprising multiple peaks, each of which is formed due to sequences of identical nucleotide size. However, for each of these discrete peaks by PCR, there can be sequences arising in different V-J regions "lumped" or clustered under the same-sized peak, which get separated by NGS such that the polyclonal background in NGS instead comprises thousands of sequences, each of which is a very small percentage in polyclonal benign conditions. Furthermore, clonal populations that are easily identifiable by PCR are also easily identified by NGS. However, as shown in our LPD cases, in contrast with PCR, NGS not only reveals the true nature of the clonal populations as biallelic (involving two V-J regions) or monoallelic (involving one V-J region) or comprising multiple clones, occasionally including two biallelic clones, but also allows quantitative determination of at least a minimum percentage composed by the clonal population, irrespective of the size of the clone as small or large, within the targeted lymphoid population. In addition, intraclonal sequence variation within neoplastic clones can be characterized only by NGS and not by PCR assays.
Our LPD FFPE cases showed a clear difference between neoplastic clones in mature T-cell lymphomas vs mature B-cell neoplasms or posttransplantation LPD cases. Much larger clones comprising greater than 44% were present in T-cell lymphomas, as well as small clones comprising less than 10% in FFPE tissues from mature B-cell neoplasms, posttransplant LPD cases, and benign cases, consistent with what we would expect in neoplasms of either T-cell or non-T-cell lineage, respectively. In addition, among our cases, NGS revealed a biallelic clonal population comprising at least 12% and likely ~17% of all T cells in the entity that was histologically suspicious for but not diagnostic of a primary cutaneous CD4+ small/ medium T-cell LPD, confirming that the T-cell clone in this neoplasm could be easily detected by NGS but was not large, consistent with the diagnosis of a nonmalignant neoplasm, as has been described for the nature of this LPD.
Interestingly, our TRG clonality results, based on criteria we used and describe above for NGS, showed findings quite similar to those by Arber et al 20 from the previous multi-institutional study of 29 lymphoid frozen and FFPE specimens that were analyzed by 24 national laboratories to evaluate T-cell clonality. The authors of that study had reported a significant overall false-negative rate (22.1% of expected T-cell gene rearrangements) for detecting T-cell clonality by using PCR assays, with the false negativity greater in FFPE compared with frozen tissues. 20 In that same study, 21 institutions reportedly used TRG PCR, and only two institutions used TRB PCR assays. 20 Similar to that multi-institution study, 20 three (23%) of 13 FFPE LPD cases in our study showed a false-negative PCR for detecting the true clonal population, which was, however, definitively detected by NGS in all false-negative PCR cases in our study. Our false-positive PCR rate (7%, one of 13 cases) for FFPE LPD cases was slightly higher than 4.1% false positives reported in that study, 20 and NGS confirmed the absence of clones in our false-positive case. While we did not examine fresh-frozen tissues, the presence of true clones in false-negative PCR cases and the absence of false-positive clones by PCR were also confirmed by NGS in nine (39%) of 23 nonfixed, fresh specimens (PB and BM) in our study. Among specimen types, our PB cases showed the highest (53%, eight of 15) false-positive or false-negative PCR results for clonality compared with NGS. Most discrepancies occurred in benign PB samples (60%, six of 10), while 12% (one of eight) BM aspirates, also benign, showed false PCR results. Possibly since the presence of clonal T-cell populations in PB is well known in nonneoplastic disease and physiologic states, most prior large studies that assessed clonality by PCR analyzed samples other than PB. [31] [32] [33] Nevertheless, our results in PB cases question the value and clinical utility of performing only PCR analysis for assessing T-cell clonality, except for detecting large, overt clones in T-cell LPDs involving PB, as was present in one of our cases, with one example being clinical staging for mycosis fungoides, in which current guidelines are for evaluating T-cell clonality by PCR or Southern blot. 34 Our study could be criticized for not including enough cases for any one clinicopathologic entity. We tried to include cases that represent routinely encountered variables in the clinical laboratory in tissues submitted for evaluation of TRG clonality. Although our study included an endoscopic biopsy specimen, we could not evaluate specimen sources from cytologic fine-needle aspiration procedures, aspirate smeared preparations on glass slides, and body fluids. Nevertheless, even within the small numbers of cases within multiple clinicopathologic entities as described, 1,2 we found that valuable information was provided by NGS in virtually every case that either confirmed or revealed new information that further explained the pathologic entity or would be helpful for clinical management. As an example, detecting small T-cell clones in the BM in a patient with a T-LGLL at clinical follow-up, as well as ruling out a T-cell clone falsely detected by PCR in PB in another patient, as we observed in our study, was possible only by NGS and not by PCR. Our T-cell lymphoma cases included a case of ALK-negative anaplastic large T-cell lymphoma, which was negative for clonality by multidistribution TRG PCR, consistent with previous studies that showed less than 100% accuracy (89% [eight of nine cases] 35 and 86% [30 of 35 cases]
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) for detecting T-cell clones in this entity. In our study case that was negative by PCR, NGS not only confirmed the presence of an overt neoplastic T-cell clone but also established the nature of the clone, including sequence variation within the clone and the relative proportions, which could possibly also be compared with the lymphoma at other sites in that patient for precise diagnostic subclassification. Notably, in addition to the negative cases by PCR that were revealed to be clonal by NGS in our study, none of the varied LPD cases from all specimen types in our study were false negative by NGS, which was 100% accurate in detecting T-LPD cases.
The findings in our study also raise questions regarding the definition and criteria for clonality in lymphoid populations as analyzed by NGS. Especially since NGS is far more sensitive than PCR in detecting rearranged V-J sequences, and since clonally expanded T cells are well known to be present in anyone in nonneoplastic disease and physiologic conditions, we believe that any definition of clonality by NGS that is applicable to all specimen tissue types would have to include clones in both neoplastic and nonneoplastic states, with clinicopathologic correlation and further follow-up or characterization necessary to ascertain the clinical significance of small clones, including to determine whether a clone is neoplastic or nonneoplastic. Analogous to the small clones present in age-related clonal hematopoiesis, which can be present in both neoplastic and nonneoplastic states, with the latter not always progressing to neoplasia, [37] [38] [39] any small lymphoid clone detected by NGS (clonal lymphopoiesis) could be physiologic or pathologic, except if that small clone is identical to a previously identified neoplastic lymphoid clone, in which case it would be neoplastic in the appropriate clinical setting.
In conclusion, we demonstrate that in the most commonly submitted clinical specimens, TRG clonality evaluation by NGS not only is technically feasible but also provides greater clinical value than PCR, both for definitively "ruling in a clone" and for "ruling out a clone," both of which are valuable to know for pathologists and clinicians for patient management. Additional studies would be valuable to further evaluate the potential clinical utility of the unique capability of NGS technology in the evaluation of clonality in hematolymphoid tissues.
